Voluntary conversion of convertible bonds into shares

In 2023 Injeq Oyj organized a share issue between June 21 and August 28, when the company received capital investment worth €880,253.05. As the investment is worth less than two million euros, the share issue triggers a “Voluntary Conversion” into company shares in accordance with the terms of the convertible bond.

If you want to convert your Bond investment into shares, please indicate your willingness between October 27, 2023 and November 10, 2023 by sending an email to IR@injeq.com and stating that you want to convert your convertible bond into Injeq Oyj shares.

Note: If the investor’s place of residence is outside Finland and his/her/its foreign bank can’t take into custody unlisted Finnish securities, and the investor is unwilling or unable to open a bookentry account in Finland, the shares will be held in the administrative register instead of the book-entry system.

Conversion of convertible bond investment into shares

The company’s board of directors decided to start the voluntary conversion on October 27, 2023 and end it on November 10, 2023, in accordance with the terms of the convertible bond (VVK). The value date was decided on November 6, 2023, when the conversion corresponds to the latest share price in the share issue of €5.65/share, including a 20% discount and 8% annual (365 days) interest on the investment

Example:

Bond investment:   €1000
Accrued interest for the period March 23, 2022- November 6,2023 €129.97
Total convertible capital €1129.97
The share price in the previous issue was €5.65/share
20% reduced price €4.52 per share
Amount to be converted €1129.97 / €4.52 = 250 shares

 

Tiedote osakkeenomistajille / Notice to shareholders

TIEDOTE INJEQ OYJ:N OSAKKEENOMISTAJILLE NOTICE TO SHAREHOLDERS OF INJEQ PLC
Read more »

News release on April 12, 2024

The share issue of Injeq Plc. ended on April 5, 2024, and the investment round did not achieve the goals […]
Read more »

Information to shareholders, March 22nd, 2024

Injeq has started a share issue. The maximum of the financing round is set at €3,000,000. If the €2,000,000 goal […]
Read more »

Injeq webinars by Dr Sauli Palmu and Dr Harri Sievänen

Injeq webinar videos are now available! Welcome to participate in Dr. Sauli Palmu’s lecture “Lumbar punctures in pediatric hemato-oncology” (part […]
Read more »

New distributor agreement with “GENFAX SRL”

We are pleased to announce that GENFAX is appointed as INJEQ’s exclusive distributor in Romania. We are confident that our […]
Read more »

Injeq webinar today, Thursday Feb 22nd, 2024

Welcome to the webinar “Innovation in lumbar punctures” on February 22nd, 2024, at 7:00 pm (Madrid time Zone)   Lecturers […]
Read more »